- Category
- Medium (2024-25)
- Udyam number
- UDYAM-MH-32-0000283

About Smruthi Organics Ltd
Data last updated:
Smruthi Organics Ltd is a public limited company based in Solapur, Maharashtra, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 11 July 1989 and has been in existence for over 37 years.
The company is registered with the Registrar of Companies (ROC), Pune, under CIN L24119PN1989PLC052562. Its GSTIN is 27AACCS5562Q1ZO (Maharashtra). The company holds 2 GST registrations, all of them active. It is a listed company as per MCA records. Its shares are listed on BSE: 540686.
The company has an authorised share capital of ₹12 Cr and a paid-up capital of ₹11.45 Cr. It is led by directors including Purushotham Malaiah Eaga (Managing Director) and Swapnil Purushotham Eaga (Managing Director).
Its last annual general meeting (AGM) was held on 20 June 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 165 A Balaji Bhavanrailway Lines, Solapur, Maharashtra, India – 413001.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹101.97 Cr, a decline of 19.1% compared to the previous year. For the same year it recorded a net profit of ₹3.75 Cr (net margin 3.7%) and EBITDA of ₹12.58 Cr (EBITDA margin 12.3%). The net worth stands at ₹73.52 Cr (up 2.6% YoY). Total assets are valued at ₹81.96 Cr (down 7.3% YoY).
The company has about 585 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Smruthi Organics. As per MCA filings, the company has open charges of ₹63.55 Cr and satisfied charges of ₹74.87 Cr on record. Court records list 45 cases involving the company, including 32 filed by the company and 13 filed against it; 12 cases are pending. The company has 20 deals on record (20 market trades); the latest was in July 2021. Its 9 peer companies in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 5 smaller; the largest is Apex Healthcare Limited with revenue of ₹127.54 Cr. The company has 8 MSME Form 1 returns on record between 2019 and 2022, listing 159 overdue payments to 17 micro and small suppliers.
Smruthi Organics Ltd is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-32-0000283). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website smruthiorganics.com.
Company details
CIN history
Smruthi Organics has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24119PN1989PLC052562, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24119PN1989PLC052562 | Current |
| U24119MH1989SGC052562 | Previous |
| U24119PN1989PLC052562 | Previous |
Recognitions & Rankings of Smruthi Organics
Contact details
Smruthi Organics Ltd's registered office is in Solapur, Maharashtra. Its website is smruthiorganics.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address165 A Balaji Bhavanrailway Lines, Solapur, Maharashtra, India – 413001
- IndustryPharma, API Manufacturers
To see the full contact details of Smruthi Organics Ltd, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Smruthi Organics operates one associated brand: Smruthi Organics. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Stainless steel and glass-lined reactors with APIs are manufactured. | smruthiorganics.com |
Business activity
The main business activity of Smruthi Organics is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Smruthi Organics Ltd, buy the company report.
Financials of Smruthi Organics Ltd
FY 2025-26 filings availableSmruthi Organics Ltd reported revenue of ₹101.97 Cr (down 19.1% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 102 | 126 | 128 | 141 | 133 | 126 | 131 |
| Revenue growth | -19.1% | -1.3% | -9.5% | +5.8% | +5.4% | -3.5% | - |
| EBITDA | 12.58 | 12.18 | 11.96 | 9.80 | 18.43 | 28.54 | 15.24 |
| EBITDA margin | +12.3% | +9.7% | +9.4% | +7.0% | +13.8% | +22.6% | +11.6% |
| Profit before tax | 4.67 | 4.90 | 4.98 | 4.52 | 13.77 | 24.06 | 12.09 |
| Net profit | 3.75 | 3.56 | 3.60 | 4.16 | 10.38 | 17.11 | 8.44 |
| Net profit margin | +3.7% | +2.8% | +2.8% | +3.0% | +7.8% | +13.5% | +6.4% |
| EPS (₹) | 2.99 | 3.11 | 3.14 | 3.61 | 9.07 | 14.95 | 22.14 |
| Balance sheet | |||||||
| Total assets | 81.96 | 88.46 | 81.41 | 74.24 | 72.67 | 73.03 | 61.40 |
| Net worth | 73.52 | 71.63 | 69.62 | 68.16 | 67.17 | 60.50 | 42.47 |
| Total debt | 8.36 | 16.80 | 11.70 | 5.70 | 2.83 | 9.90 | 15.66 |
| Cash & bank | 2.27 | 0.51 | 0.57 | 1.75 | 0.57 | 16.14 | 3.57 |
| Net working capital | 31.83 | 40.92 | 39.50 | 34.94 | 39.63 | 42.52 | 28.78 |
| Cash flow | |||||||
| Cash from operations | 22.26 | 9.98 | 4.40 | 12.11 | 2.17 | 22.82 | 21.43 |
| Cash from investing | (8.92) | (11.42) | (7.16) | (10.25) | 7.15 | (3.40) | (4.52) |
| Cash from financing | (12.07) | 1.40 | 2.66 | (1.52) | (12.11) | (6.86) | (17.49) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 29.30 | 29.05 | 22.29 | 31.60 | 18.85 | 38.09 | 31.25 | 29.39 |
| Revenue growth (YoY) | +55.4% | -23.7% | -28.7% | +7.5% | -30.9% | - | - | - |
| Other income | 0.03 | 0.02 | 0.01 | 0.01 | 0.09 | 0.08 | 0.00 | 0.01 |
| Total expenses | 23.55 | 25.24 | 18.74 | 26.59 | 18.61 | 33.42 | 27.09 | 26.50 |
| EBITDA | 5.75 | 3.81 | 3.55 | 5.01 | 0.24 | 4.67 | 4.16 | 2.89 |
| EBITDA margin | +19.6% | +13.1% | +15.9% | +15.9% | +1.3% | +12.3% | +13.3% | +9.8% |
| Depreciation | 1.60 | 1.75 | 1.67 | 1.51 | 1.41 | 1.50 | 1.37 | 1.33 |
| Interest | 0.31 | 0.31 | 0.25 | 0.66 | 0.46 | 0.52 | 0.51 | 0.44 |
| Profit before tax | 3.87 | 1.77 | 1.64 | 2.85 | (1.54) | 2.73 | 2.28 | 1.13 |
| Tax | 0.99 | 0.70 | 0.24 | 0.79 | (0.44) | 0.51 | 0.81 | 0.36 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 29.30 | 29.05 | 22.29 | 31.60 | 18.85 | 38.09 | 31.25 | 29.39 |
| Revenue growth (YoY) | +55.4% | -23.7% | -28.7% | +7.5% | -30.9% | - | - | - |
| Other income | 0.03 | 0.02 | 0.01 | 0.01 | 0.09 | 0.08 | 0.00 | 0.01 |
| Total expenses | 23.55 | 25.24 | 18.74 | 26.59 | 18.61 | 33.42 | 27.09 | 26.50 |
| EBITDA | 5.75 | 3.81 | 3.55 | 5.01 | 0.24 | 4.67 | 4.16 | 2.89 |
| EBITDA margin | +19.6% | +13.1% | +15.9% | +15.9% | +1.3% | +12.3% | +13.3% | +9.8% |
| Depreciation | 1.60 | 1.75 | 1.67 | 1.51 | 1.41 | 1.50 | 1.37 | 1.33 |
| Interest | 0.31 | 0.31 | 0.25 | 0.66 | 0.46 | 0.52 | 0.51 | 0.44 |
| Profit before tax | 3.87 | 1.77 | 1.64 | 2.85 | (1.54) | 2.73 | 2.28 | 1.13 |
| Tax | 0.99 | 0.70 | 0.24 | 0.79 | (0.44) | 0.51 | 0.81 | 0.36 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 102 | 126 | 128 | 141 | 133 | 126 | 131 |
| Revenue growth | -19.1% | -1.3% | -9.5% | +5.8% | +5.4% | -3.5% | - |
| Other income | 0.12 | 0.09 | 0.08 | 0.11 | 0.58 | 0.56 | 4.42 |
| Total expenses | 89.39 | 114 | 116 | 131 | 115 | 97.96 | 116 |
| Employee cost | 17.56 | 17.35 | 17.16 | 15.82 | 13.73 | 15.64 | 13.57 |
| EBITDA | 12.58 | 12.18 | 11.96 | 9.80 | 18.43 | 28.54 | 15.24 |
| EBITDA margin | +12.3% | +9.7% | +9.4% | +7.0% | +13.8% | +22.6% | +11.6% |
| Depreciation | 6.35 | 5.50 | 5.65 | 4.57 | 4.26 | 3.95 | 4.39 |
| Interest | 1.68 | 1.87 | 1.41 | 0.82 | 0.98 | 1.09 | 3.18 |
| Profit before tax | 4.67 | 4.90 | 4.98 | 4.52 | 13.77 | 24.06 | 12.09 |
| Tax | 1.24 | 1.34 | 1.38 | 0.36 | 3.39 | 6.95 | 3.65 |
| Net profit | 3.75 | 3.56 | 3.60 | 4.16 | 10.38 | 17.11 | 8.44 |
| Net profit margin | +3.7% | +2.8% | +2.8% | +3.0% | +7.8% | +13.5% | +6.4% |
| EPS (₹) | 2.99 | 3.11 | 3.14 | 3.61 | 9.07 | 14.95 | 22.14 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 11.45 | 11.45 | 11.45 | 11.45 | 11.45 | 11.45 | 3.82 |
| Reserves & surplus | 62.07 | 60.18 | 58.17 | 56.71 | 55.72 | 49.05 | 38.65 |
| Shareholders' funds (net worth) | 73.52 | 71.63 | 69.62 | 68.16 | 67.17 | 60.50 | 42.47 |
| Secured loans | 8.26 | 16.80 | 11.70 | 5.59 | 1.98 | 0.00 | 0.00 |
| Unsecured loans | 0.10 | 0.00 | 0.00 | 0.11 | 0.85 | 9.90 | 15.66 |
| Total debt | 8.36 | 16.80 | 11.70 | 5.70 | 2.83 | 9.90 | 15.66 |
| Total liabilities | 81.96 | 88.46 | 81.41 | 74.24 | 72.67 | 73.03 | 61.40 |
| Assets | |||||||
| Gross block | 149 | 141 | 130 | 122 | 114 | 107 | 104 |
| Net block | 46.89 | 44.97 | 39.99 | 37.03 | 33.34 | 31.00 | 31.71 |
| Capital work in progress | 2.97 | 2.55 | 1.43 | 1.99 | 0.80 | 0.84 | 0.19 |
| Investments | 0.20 | 0.16 | 0.13 | 0.12 | 0.05 | 0.05 | 0.05 |
| Inventories | 28.35 | 28.31 | 29.78 | 23.99 | 19.93 | 18.13 | 17.09 |
| Sundry debtors | 19.30 | 32.47 | 41.03 | 36.96 | 28.50 | 21.35 | 24.57 |
| Cash & bank balances | 2.27 | 0.51 | 0.57 | 1.75 | 0.57 | 16.14 | 3.57 |
| Loans & advances | 2.78 | 2.04 | 4.05 | 2.61 | 3.51 | 3.46 | 7.81 |
| Total current assets | 52.70 | 63.33 | 75.43 | 65.31 | 52.51 | 59.08 | 53.04 |
| Total current liabilities | 20.87 | 22.41 | 35.93 | 30.37 | 12.88 | 16.56 | 24.26 |
| Net working capital | 31.83 | 40.92 | 39.50 | 34.94 | 39.63 | 42.52 | 28.78 |
| Total assets | 81.96 | 88.46 | 81.41 | 74.24 | 72.67 | 73.03 | 61.40 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.44 | 0.48 | 0.59 | 0.24 | 3.03 | 3.57 | 4.16 |
| Net cash from operating activities | 22.26 | 9.98 | 4.40 | 12.11 | 2.17 | 22.82 | 21.43 |
| Net cash from investing activities | (8.92) | (11.42) | (7.16) | (10.25) | 7.15 | (3.40) | (4.52) |
| Net cash from financing activities | (12.07) | 1.40 | 2.66 | (1.52) | (12.11) | (6.86) | (17.49) |
| Net change in cash | 1.27 | (0.04) | (0.11) | 0.34 | (2.79) | 12.57 | (0.58) |
| Closing cash | 2.27 | 0.51 | 0.57 | 1.75 | 0.57 | 16.14 | 3.57 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -19.1% | -1.3% | -9.5% | +5.8% | +5.4% | -3.5% | - |
| EBITDA growth | +3.3% | +1.8% | +22.0% | -46.8% | -35.4% | +87.3% | - |
| PBT growth | -4.7% | -1.6% | +10.2% | -67.2% | -42.8% | +99.0% | +24.0% |
| Net income growth | +5.3% | -1.1% | -13.5% | -59.9% | -39.3% | +102.7% | - |
| Revenue CAGR (3Y) | -10.3% | -1.9% | +0.3% | +2.5% | -1.0% | +9.1% | +18.2% |
| EBITDA CAGR (3Y) | +8.7% | -12.9% | -25.2% | -13.7% | +3.6% | +106.3% | +15.3% |
| Profitability & leverage | |||||||
| Net income margin | +3.4% | +2.8% | +2.8% | +3.0% | +7.8% | +13.5% | +6.4% |
| Return on capital employed | +7.5% | +8.0% | +8.2% | +7.2% | +20.2% | +37.4% | +23.7% |
| Return on net worth | +4.7% | +5.0% | +5.2% | +6.1% | +16.3% | +33.2% | +21.4% |
| Debt / equity | 0.17 | 0.20 | 0.13 | 0.06 | 0.10 | 0.25 | 0.55 |
| Long-term debt / equity | 0.07 | 0.10 | 0.04 | 0.01 | 0.00 | 0.04 | 0.06 |
| Interest cover | 26.97 | 27.99 | 22.35 | 15.68 | 6.92 | 4.43 | 29.31 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.70 | 0.93 | 1.01 | 1.19 | 1.21 | 1.20 | 1.30 |
| Inventory turnover | 3.60 | 4.34 | 4.75 | 6.42 | 7.01 | 7.18 | 6.59 |
| Debtors turnover | 3.94 | 3.43 | 3.27 | 4.31 | 5.35 | 5.51 | 4.30 |
| EPS (₹) | 2.99 | 3.11 | 3.14 | 3.61 | 9.07 | 14.95 | 22.14 |
| Dividend per share (₹) | 1.50 | 1.50 | 1.50 | 2.00 | 3.00 | 3.00 | 3.00 |
| Book value per share (₹) | 64.22 | 62.58 | 60.82 | 59.54 | 58.68 | 52.85 | 111.29 |
To see the full year-wise statements and ratios of Smruthi Organics Ltd, buy the company report.
Board of directors of Smruthi Organics Ltd
Smruthi Organics has 6 current directors and 10 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Purushotham Malaiah Eaga | Managing Director | 01 Aug 2010 | 16 Years 3 Months | Current |
| Smruthi Purushotham Eaga | Director | 12 Feb 2022 | 4 Years 8 Months | Current |
| Swapnil Purushotham Eaga Also directs: Smruthi Chemicals and Intermediates LLP, Turtle Infratrade Limited | Managing Director | 06 Apr 2009 | 17 Years 7 Months | Current |
| Prakash Purushottam Wadgaonkar Also directs: Nuons Organic Private Limited, Appaji Dwarkoji Madane Foundation | Director | 29 Jul 2024 | 2 Years 3 Months | Current |
| Anoop Anil Doshi | Director | 29 Jul 2024 | 2 Years 3 Months | Current |
| Dharmaraj Ramachandra Rao | Director | 29 Jul 2024 | 2 Years 3 Months | Current |
Peer comparison
Smruthi Organics Ltd is compared with the 9 companies closest to it by revenue in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Apex Healthcare Limited | ₹127.54 Cr (FY 2025) | 64.0% | Surat, Gujarat, India | |||
| Coral Drugs Private Limited | ₹126.9 Cr (FY 2025) | 11.0% | New Delhi, Delhi, India | |||
| Sohan Healthcare Private Limited | ₹126.69 Cr (FY 2025) | 6.0% | Yavatmal, Maharashtra, India | |||
| Corey Organics Private Limited | ₹126.33 Cr (FY 2025) | -6.0% | Hyderabad, Telangana, India | |||
| Alcon Biosciences Private Limited | ₹125.22 Cr (FY 2025) | 10.0% | Mumbai, Maharashtra, India | |||
| Quad Lifesciences Private Limited | ₹123.66 Cr (FY 2025) | 26.0% | Derabassi, Punjab, India | |||
| Roopa Industries Limited | ₹122.98 Cr (FY 2025) | 72.0% | Kurnool, A.P, Andhra Pradesh, India | |||
| Richter Themis Medicare (India) Private Limited | ₹122.69 Cr (FY 2025) | -13.0% | Valsad, Gujarat, India | |||
| Nuray Chemicals Private Limited | ₹122.27 Cr (FY 2025) | 16.0% | Thiruvallur, Tamil Nadu, India | |||
| Smruthi Organics Ltdthis company | ₹101.97 Cr (FY 2026) | ₹3.75 Cr | 3.7% | -19.1% | 585 | Solapur, Maharashtra, India |
To see the full peer comparison of Smruthi Organics Ltd, buy the company report.
Auditor
Smruthi Organics Ltd is audited by GOKHALE AND SATHE for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| GOKHALE AND SATHE | FY 2023 | 103264W |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 64.70%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 35.30%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 64.70% | 64.70% | 64.70% | 64.70% |
| Public | 35.30% | 35.30% | 35.30% | 35.30% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 31 Aug 2023 | 100781773 | Axis Bank Limited | ₹17 Cr | Open | |
| 15 Feb 2001 | 80013457 | State Bank of India | ₹46.55 Cr | Open | |
| 27 Feb 2023 | 100687533 | Axis Bank Limited | ₹87 Lakh | Satisfied | |
| 17 Dec 2012 | 10398153 | Axis Bank Limited | ₹19.25 Cr | Satisfied | |
| 15 Feb 2007 | 10044312 | Sbi Factors and Commercial Services (P) Limited | ₹54.75 Cr | Satisfied |
To see the full charge records of Smruthi Organics Ltd, buy the company report.
Total charge records: 5 View all charges
Deals & funding
Smruthi Organics Ltd has 20 deals on record (20 market trades); the latest was in July 2021.
Deals on record (5 of 20)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jul 2021 | Market trade | ₹2 Cr | Buyer: Alpha Leon Enterprises LLP Seller: Alpha Leon Enterprises LLP |
| Jul 2021 | Market trade | ₹2.86 Cr | Buyer: Alpha Leon Enterprises LLP Seller: Alpha Leon Enterprises LLP |
| Jan 2021 | Market trade | ₹2.43 Cr | Seller: Rajasthan Global Securities Private Limited |
| Jan 2018 | Market trade | ₹50.9 Lakh | Buyer: Rajasthan Global Securities Private Limited Seller: an individual |
| Sep 2014 | Market trade | ₹17.2 Lakh | Buyer: Rajasthan Global Securities Private Limited |
To see the full deal history of Smruthi Organics Ltd, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Smruthi Organics Ltd has 45 court cases on record: 32 filed by Smruthi Organics, 13 filed against it. 12 cases are pending and 33 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 29 | 3 | 8 |
| High courts | 16 | 10 | 4 |
Cases on record (5 of 45)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Solapur, Maharashtra | Civil suit | Filed by the company against Goldfish Pharma Private Ltd and 3 others | Pending |
| District court, Solapur, Maharashtra | Civil suit | Filed by the company against Ariston Pharma Novatech Pvt Ltd and 2 others | Pending |
| District court, Solapur, Maharashtra | Civil suit | Filed by the company against Chemsol Labs Pvt Ltd and 2 others | Disposed |
| District court, Maharashtra Industrial and Lab, Maharashtra | Interim or miscellaneous application | Filed by the company against National Insurance Company Ltd. | Disposed |
| District court, Solapur, Maharashtra | Court case (Civil M.A.) | Filed by the company against an individual | Pending |
To see the full case history of Smruthi Organics Ltd, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Smruthi Organics Ltd was last rated by Care on 05 Jan 2022.
| Rating agency | Rated on | Rating |
|---|---|---|
| Care | 05 Jan 2022 |
To see the full credit ratings and regulatory alerts of Smruthi Organics Ltd, buy the company report.
MSME payment delays
Smruthi Organics Ltd has 8 MSME Form 1 returns on record between 2019 and 2022, listing 159 overdue payments to 17 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 17)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| JPS Chemicals Private Limited | |||
| SKF India Limited | |||
| an individual supplier | |||
| Standard Reagents Private Limited | |||
| Ad Pharma Equipment Private Limited |
To see the full MSME payment records of Smruthi Organics Ltd, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Smruthi Organics Ltd has a workforce of 585 employees on its EPFO records as of Apr 01, 2024, across 2 active EPFO establishments.
GST
Smruthi Organics has 2 GST registrations: 2 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AACCS5562Q1ZO | Maharashtra | Active | 01 Jul 2017 |
| 36AACCS5562Q1ZP | Telangana | Active | 11 Dec 2018 |
To see the full GST registrations and return filing status of Smruthi Organics Ltd, buy the company report.
Recent activity
Smruthi Organics Ltd has 24 board changes on record since 1994: 15 appointments and 9 cessations. The latest: Anoop Anil Doshi was appointed as Director on 29 Jul 2024.
26 earlier events are in the company report.
News
Frequently asked questions
Smruthi Organics is an active public limited company based in Solapur, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 11 July 1989 (37+ years old) and is registered under CIN L24119PN1989PLC052562. Listed on BSE: 540686.
Smruthi Organics reported revenue of ₹101.97 Cr for FY 2025-26 (down 19.1% YoY) based on standalone financials.
Smruthi Organics has 6 current directors:
- Purushotham Malaiah Eaga - Managing Director
- Swapnil Purushotham Eaga - Managing Director
- Smruthi Purushotham Eaga - Director
- Prakash Purushottam Wadgaonkar - Director
- Anoop Anil Doshi - Director
- Dharmaraj Ramachandra Rao - Director
The latest financial statements of Smruthi Organics on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 20 June 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Smruthi Organics is 27AACCS5562Q1ZO, registered in Maharashtra. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 36AACCS5562Q1ZP (Telangana).
The CIN (Corporate Identification Number) of Smruthi Organics is L24119PN1989PLC052562. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Smruthi Organics is a listed company as per MCA records. Its shares are listed on BSE (code: 540686).
Smruthi Organics has 45 court cases on record: 32 filed by the company and 13 filed against it. 12 are pending. Most are in the district courts.
Smruthi Organics was incorporated on 11 July 1989, making it 37+ years old. It is registered with the Registrar of Companies, Pune.
Smruthi Organics has 20 deals on record (20 market trades); the latest was in July 2021.
The peers of Smruthi Organics by revenue are Apex Healthcare Limited, Coral Drugs Private Limited, Sohan Healthcare Private Limited, Corey Organics Private Limited, Alcon Biosciences Private Limited and 4 more, all in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Anoop Anil Doshi was appointed as Director on 29 Jul 2024. Dharmaraj Ramachandra Rao was appointed as Director on 29 Jul 2024. Prakash Purushottam Wadgaonkar was appointed as Director on 29 Jul 2024. Smruthi Organics has 24 board changes on record in total.

